Prevalence of transmitted HIV drug resistance since the availability of highly active antiretroviral therapy

Authors

  • Jessica S Russell HIV Characterisation Laboratory, Victorian Infectious Diseases Reference Laboratory, North Melbourne Victoria
  • Doris Chibo HIV Characterisation Laboratory, Victorian Infectious Diseases Reference Laboratory, North Melbourne Victoria
  • Matthew B Kaye HIV Characterisation Laboratory, Victorian Infectious Diseases Reference Laboratory, North Melbourne Victoria
  • Megan L Gooey HIV Characterisation Laboratory, Victorian Infectious Diseases Reference Laboratory, North Melbourne Victoria
  • Louise A Carolan HIV Characterisation Laboratory, Victorian Infectious Diseases Reference Laboratory, North Melbourne Victoria
  • Anastasia Papadakis HIV Characterisation Laboratory, Victorian Infectious Diseases Reference Laboratory, North Melbourne Victoria
  • Jodie A Nicholls HIV Characterisation Laboratory, Victorian Infectious Diseases Reference Laboratory, North Melbourne Victoria
  • Chris J Birch HIV Characterisation Laboratory, Victorian Infectious Diseases Reference Laboratory, North Melbourne Victoria

DOI:

https://doi.org/10.33321/cdi.2009.33.22

Keywords:

HIV, transmitted drug resistance, antiretroviral therapy

Abstract

We investigated the prevalence of HIV-1-associated transmitted drug resistance (TDR) in Victoria from the time of first availability of highly active antiretroviral therapy. Drug resistance genotyping was performed on virus present in blood samples collected from individuals with serologically confirmed primary infection, between 1996 and 2007. The significance of any mutations detected was interpreted according to a standardised list of drug resistance mutations. The main outcomes measured were the prevalence by year of TDR to any antiretroviral drug class, the numbers of infected individuals with TDR involving multiple drug classes, and the resistance mutations implicated in all cases. There was an average annual prevalence of TDR of 16%, predominantly associated with nucleoside and non-nucleoside reverse transcriptase (RT) inhibitors and most commonly occurring at codons 41, 103 and 215 in the RT. The prevalence of thymidine-associated mutations remained high throughout the period of study. While mutations known to cause resistance to protease inhibitors were uncommon, they were present in several individuals infected with virus resistant to multiple drug classes. The prevalence of TDR in Victoria is similar to geographical locations outside Australia where HIV-specific drug treatment is widely available. Primary infection with drug resistant HIV is a future treatment issue for the individual patient and for the wider population at risk of infection. At this time TDR shows no sign of waning and our data support recent treatment guidelines recommending baseline testing for TDR before therapy is initiated. Commun Dis Intell 2009;33:216–220.

Downloads

Download data is not yet available.

References

Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288(2):181–188.

Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiviral drug resistance among patients recently infected with HIV. N Engl J Med 2002;347(6):385–394.

Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002;16(11):1511–1519.

Ibe S, Hotta N, Takeo U, Tawada Y, Mamiya N, Yamanaka K, et al. Prevalence of drug-resistant human immunodeficiency virus type 1 in therapy-naïve patients and usefulness of genotype testing. Microbiol Immunol 2003;47(7):499–505.

Shet A, Berry L, Mohri H, Mehandru S, Chung C, Kim A, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr 2006;41(4):439–446.

Choi JY, Kim EJ, Park YK, Lee JS, Kim SS. National survey for drug-resistant variants in newly diagnosed antiretroviral drug-naïve patients with HIV/AIDS in South Korea: 1999–2005. J Acquir Immune Defic Syndr 2008;49(3):237–242.

Barth RE, Wensing AM, Tempelman HA, Moraba R, Schuurman R, Hoepelman AI. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa. AIDS 2008;22(8):2210–2212.

Masquelier B, Bhaskaran K, Pillay D, Gifford R, Balestre E, Jørgensen LB, et al. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquire Immune Defic Syndr 2005;40(5):505–511.

Peuchant O, Capdepont S, Ragnaud JM, Aurillac-Lavignolle V, Thiébaut R, Fleury H, et al. Primary resistance to enfuvirtide (T20) in recently infected, antiretroviral-naïve patients from the ANRS Aquitane cohort. Antivir Ther 2007,12(4):559–562.

Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, et al. Mutations associated with failure of Raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008;52(4):1351–1358.

Pillay D, Bhaskaran K, Jurriaans S, Prins M, Masquelier B, Dabis F, et al. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 2006,20(1):21–28.

Oette M, Kaiser R, Däumer M, Petch R, Fätkenheuer G, Carls H, et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquire Immune Defic Syndr 2006;41(5):573–581.

Australasian Society for HIV Medicine. Australian Commentary on Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents [Online]. Available from: http://www.ashm.org.au/images/publications/guidelines/dhhsadult_04_03_09%20-%20final.pdf

Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007;21(2):215–223.

Guy RJ, Breschkin AM, Keenan CM, Catton MG, Enriquez AM, Hellard ME. Improving HIV surveillance in Victoria: the role of the detuned enzyme immunoassay. J Acquir Immune Defic Syndr 2005; 38(4):495–499.

Middleton T, Smith D, Larder B, Law M, Birch C. Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy. HIV Clin Trials 2001;2(6):445–452.

Chibo D, Roth N, Roulet V, Skrabal K, Gooey M, Carolan L, et al. Virological fitness of HIV in patients with resistance to enfuvirtide. AIDS 2007;21(14):1974–1977.

White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 2002;46(11):3437–3446.

Wainberg MA. The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev Anti Infect Ther 2004;2(1):147–151.

Kaye M, Chibo D, Birch C. Phylogenetic investigation of transmission pathways of drug-resistant HIV-1 utilising pol sequences derived from resistance testing. J Acquir Immune Defic Syndr 2008;49(1):9–16.

Ammaranond P, Cunningham P, Oelrichs R, Suzuki K, Harris C, Leas L, et al. No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infection: 1992–2001. AIDS 2003;17(2):264–267.

Yerly S, von Wyl V, Ledergerber B, Böni J, Schüpbach J, Bürgisser P, et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 2007;21(16):2223–2229.

Downloads

Published

01/06/09

How to Cite

Russell, Jessica S, Doris Chibo, Matthew B Kaye, Megan L Gooey, Louise A Carolan, Anastasia Papadakis, Jodie A Nicholls, and Chris J Birch. 2009. “Prevalence of Transmitted HIV Drug Resistance since the Availability of Highly Active Antiretroviral Therapy”. Communicable Diseases Intelligence 33 (June):216-20. https://doi.org/10.33321/cdi.2009.33.22.

Issue

Vol. 33 (2009)

Section

Original article

Categories

License

Copyright (c) 2009 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)